Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
Open Access
- 19 September 2024
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 996
Abstract
High-density lipoprotein (HDL) cholesterol is traditionally viewed as protective against cardiovascular disease (CVD). However, emerging evidence reveals that dysfunctional HDL, characterized by impaired reverse cholesterol transport (RCT), reduced anti-inflammatory and antioxidant activities and increased endothelial dysfunction, which can contribute to coronary artery disease (CAD). Dysfunctional HDL, resulting from oxidative modifications of Apolipoprotein A-1 (Apo A-1) and enzyme inactivation, fails to effectively remove cholesterol from peripheral tissues and may promote inflammation and atherosclerosis. Genetic mutations affecting HDL metabolism further complicate its role in cardiovascular health. Studies have shown that conventional therapies aimed at raising HDL-C levels do not necessarily reduce cardiovascular events, highlighting the need for new approaches that improve HDL functionality. Therapeutic strategies such as Apo A-1 mimetic peptides, reconstituted HDL infusions, and drugs targeting specific HDL metabolic pathways are being explored. Additionally, weight loss, statin therapy, and niacin have shown potential in enhancing HDL function. The pathophysiology of dysfunctional HDL involves complex mechanisms, including oxidative stress, inflammation, and genetic mutations, which alter its structure and function, diminishing its cardioprotective effects. New functional assays, such as the cholesterol efflux capacity (CEC) and HDL inflammatory index, provide more accurate predictions of cardiovascular risk by assessing HDL quality rather than quantity. As research progresses, the focus is shifting towards therapeutic strategies that enhance HDL function and address the root causes of its dysfunction, offering a more effective approach to reducing cardiovascular risk and preventing CAD.Keywords
This publication has 62 references indexed in Scilit:
- High density lipoprotein: When to rethink too much of a good thingAmerican Journal of Preventive Cardiology, 2023
- Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and TreatmentsCurrent Problems in Cardiology, 2022
- Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologiesMolecular Biology Reports, 2021
- Endothelial lipase increases eNOS activating capacity of high-density lipoproteinBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2020
- Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) TrialClinical Therapeutics, 2019
- The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels But Not Metrics of FunctionalityJACC, 2013
- Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular diseaseEMBO Molecular Medicine, 2012
- Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging studyAmerican Heart Journal, 2012
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapyAmerican Heart Journal, 2009